## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  RAYNOR DANIEL						2. Issuer Name <b>and</b> Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ ANIP ]									ck all app	licable) tor		Person(s) to Issuer	
		CEUTICALS, II	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 03/15/2018									Officer (give title below)		Other below	(specify	
210 MAIN STREET WEST  (Street)  BAUDETTE MN 56623  (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tabl	e I - N	on-Deriv	ative	Seci	uritie	s Ac	quire	d, Di	sposed o	f, or B	enefic	ially	/ Own	ed			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/				Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a			Benefic Owned		ies ially Following	Form (D) o	n: Direct or Indirect ostr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price			ted action(s) 3 and 4)			(Instr. 4)	
Common Stock 03/15/20				2018	18		S		1,902	D	\$61.	5(1)	294,316			T I	See Footnote <sup>(2)</sup>		
Common Stock 03/19/20				2018	18		S		5,313	D	\$60.6	62 <sup>(3)</sup>	289,003				See Footnote <sup>(2)</sup>		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) i	Execut if any	3A. Deemed Execution Date, if any (Month/Day/Year)		ction Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		ate	7. Title Amoun Securit Underly Derivat Securit and 4)	t of ies ying ive y (Instr. 3	De Se (In	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code		(A) (D)		Date Exercisable		Expiration Date	Number of Shares								

## **Explanation of Responses:**

- 1. This transaction was executed in multiple trades at prices ranging from \$61.00 to \$62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- $2. \ Held \ by \ Argentum \ Capital \ Partners \ II. \ L.P., \ which \ the \ Reporting \ Person \ may \ be \ deemed \ to \ be \ a \ beneficial \ owner \ pursuant \ to \ rule \ 16a-1(a)(1).$
- 3. This transaction was executed in multiple trades at prices ranging from \$60.50 to \$60.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

<u>/s/ Daniel Raynor</u> <u>03/19/2018</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.